Videos

beauty

"She walks in beauty, like the night, Of cloudless climes and starry skies; And all that’s best of dark and bright, Meet in her aspect and her eyes..."

1 expert is featured in this series.

Melanie Barrett, MD; Anita Clayton, MD, and Carmen Kosicek, MSN, PMHNP-BC, discuss how optimizing SSRI dosage, potentially augmenting with another medication class, and intensifying psychosocial support helps address breakthrough PPD symptoms in mothers with partial response to current SSRI treatment.

1 expert is featured in this series.

Melanie Barrett, MD; Anita Clayton, MD, and Carmen Kosicek, MSN, PMHNP-BC, discuss how a mother's persistent PPD symptoms despite SSRI treatment necessitated a comprehensive reevaluation of medication dosage, additional therapeutic interventions, and closer monitoring of treatment response to achieve better symptom control.

1 expert is featured in this series.

Melanie Barrett, MD; Anita Clayton, MD, and Carmen Kosicek, MSN, PMHNP-BC, discuss how prompt intervention combining psychotherapy, social support mobilization, and potential medication options provides comprehensive care for the mother experiencing PPD symptoms at 12 weeks, with emphasis on both immediate symptom relief and long-term recovery strategies.

1 expert is featured in this series.

Melanie Barrett, MD; Anita Clayton, MD, and Carmen Kosicek, MSN, PMHNP-BC, discuss how a mother's PPD symptoms emerged gradually through increasing anxiety, intrusive thoughts, and emotional detachment, ultimately leading her to seek professional help after her partner noticed concerning behavioral changes at 12 weeks postpartum.

1 expert is featured in this series.

Melanie Barrett, MD; Anita Clayton, MD, and Carmen Kosicek, MSN, PMHNP-BC, discuss how postpartum depression treatments are evolving beyond traditional antidepressants to include rapid-acting options like brexanolone and zuranolone, along with enhanced screening and support programs for new mothers.

Panelists discuss how faster-acting treatments like zuranolone might improve patient outcomes and quality of life, the initial signs to monitor for assessing effectiveness, barriers to accessing such therapies in underserved populations and strategies to increase accessibility, approaches to ensuring safety while addressing distress in patients with intrusive thoughts, effective strategies for managing sleep issues in postpartum depression (PPD), advice for the psychiatry community when treating PPD, and how to tailor advice for clinicians working with underserved populations.

Panelists discuss when to adjust the dosage of current therapies like sertraline vs considering alternative treatments and the factors that guide these decisions, as well as whether treatments with rapid onset, such as zuranolone capsules or brexanolone intravenous (IV) infusion, would be appropriate for cases like Sarah’s, and what factors would influence the choice between these options.